Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biohaven Pharmaceutical Holding Company Ltd (NY: BHVN )

73.65 USD +1.32 (+1.82%)
Official Closing Price Updated: 7:00 PM EDT, Apr 20, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biohaven Pharmaceutical Holding Company Ltd

< Previous 1 2 3 4 5 6 Next >
Biohaven Highlights Neuroscience Advancements with 22 Presentations at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting
- Pivotal trial of rimegepant for the preventive treatment of migraine spotlights reduction of 4.3 monthly migraine days during weeks 9-12 and rapid onset of preventive effects observed within the... 
From PR Newswire
Biohaven Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT
- NURTEC® ODT achieved preliminary net product revenue of approximately $43.8 million for the first quarter of 2021 
From PR Newswire
Rick Ware Racing, Biohaven's Nurtec ODT and Nine Line Apparel Honor Fallen Service Members
- Fallen service members names added to car hoods for respective branches of military served - 
From PR Newswire
Biohaven Enrolls First Patient in Phase 2/3 Trial of Oral Zavegepant, Prompting $100 Million Milestone Funding Payment from Royalty Pharma
-- Zavegepant is a high affinity, selective and structurally unique, third generation, CGRP receptor antagonist in development for both migraine and non-migraine CGRP-mediated diseases 
From PR Newswire
Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial–stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative,... 
From PR Newswire
Biohaven Announces Proposed Public Offering Of Common Shares
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative,... 
From PR Newswire
Biohaven's NURTEC® ODT Approved In United Arab Emirates For Acute Treatment Of Migraine
- NURTEC ODT obtained market authorization in the United Arab Emirates, along with the recent approval in Israel 
From PR Newswire
Biohaven Announces Completion Of 50% Enrollment Ahead Of Timelines In Verdiperstat Pivotal HEALEY ALS Platform Trial At Massachusetts General Hospital
- Biohaven's verdiperstat was selected as one of the first three drug candidates to be studied in the innovative HEALEY ALS Platform Trial at MGH 
From PR Newswire
Biohaven's NURTEC® ODT Approved In Israel For Acute Treatment Of Migraine
- NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT) 
From PR Newswire
Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics
From GlobeNewswire News Releases
Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments
- NURTEC® ODT (rimegepant) net product revenues for the fourth quarter of 2020 were $35.1 million, representing a 98% increase compared to the third quarter of 2020, and $63.6 million for calendar year... 
From PR Newswire
Biohaven To Report Fourth Quarter And Full Year 2020 Financial Results And Recent Business Developments On March 1, 2021
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and... 
From PR Newswire
Biohaven's BHV-1200, A Multimodal Antibody Therapy Enhancer (MATE), Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19
-Biohaven's proprietary MATE™ conjugation platform has been used to generate a new class of antibody-based therapies to target COVID-19 
From PR Newswire
Biohaven Provides Update On ESG Practices
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates today announced the... 
From PR Newswire
Frazier Healthcare Partners Adds Highly Experienced Investor to Life Sciences Team
Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years of experience investing in public and private... 
From Business Wire News Releases
Biohaven Announces Preliminary 4Q2020 Net Product Revenue For NURTEC® ODT
- NURTEC® ODT achieved preliminary net product revenue of approximately $35 million for the fourth quarter of 2020, representing an approximately 98% increase from the prior quarter 
From PR Newswire
Biohaven Signs Cody Ware as Driver for Nurtec® ODT Chevrolet for the 2021 NASCAR Cup Series Season
Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Cody Ware will pilot the Nurtec® ODT (rimegepant) #51 Chevrolet Camaro for Rick Ware Racing during the 2021 NASCAR Cup Series season. The first... 
From PR Newswire
Biohaven Provides Update On Phase 2/3 Trial And Alzheimer's Disease Program
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that it has completed a focused analysis of the topline co-primary and key secondary data from its Phase 2/3 clinical trial of... 
From PR Newswire
Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs
- Acquires full ownership of Kleo Pharmaceuticals with two novel immune modulating platforms: the Multi-targeted Antibody Therapy Enhancer (MATE™) conjugation platform and Antibody Recruiting Molecule... 
From PR Newswire
Biohaven's Nurtec® ODT Partners with Rick Ware Racing for 24 Hours of Daytona Entry
Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Nurtec® ODT (rimegepant) will be the primary sponsor on the #51 Ligier JS P217 entry into the LMP2 class of the 2021 24 Hours of Daytona.... 
From PR Newswire
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
- Recently completed Phase 2 proof of concept study showed drug signal for troriluzole augmentation in OCD and pivotal Phase 3 trial now initiated 
From PR Newswire
Biohaven's Rimegepant For Preventive Treatment Of Migraine Published In The Lancet
- Rimegepant 75 mg, already approved for the acute treatment of migraine, demonstrated efficacy and safety for the preventive treatment of migraine in this pivotal Phase 3 trial in adults 
From PR Newswire
Kleo Pharmaceuticals Presents Preclinical Data on KPMW135, a Novel CD3 x CD20 Bispecific Version of Rituximab, Showing Increased Anti-Tumor Activity Compared to Rituximab, at The 62nd Annual American
Proof-of-Concept Data Demonstrates Broad Therapeutic Potential of Company’s Multi-targeted Antibody Therapy Enhancer (MATE™) Platform 
From GlobeNewswire News Releases
Biohaven's Nurtec™ ODT Partners with the Rick Ware Racing Team in the 2021 NASCAR Cup Series
Biohaven Pharmaceuticals (NYSE:BHVN) announces today that Nurtec™ ODT (rimegepant) will be the primary partner for the No. 51 Rick Ware Racing entry during the entire 2021 NASCAR Cup Series Season,... 
From PR Newswire
Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio
- Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists 
From PR Newswire
Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE™) at The 62nd Annual Society of Hematology (ASH) Meeting
From GlobeNewswire News Releases
BioShin enrolls first patient into an Asia-Pacific regional multi-center phase III clinical trial of rimegepant (BHV-3000) for the acute treatment of migraine.
From GlobeNewswire News Releases
Value-based agreement between Prime Therapeutics and Biohaven aims to bring NURTEC™ ODT acute migraine treatment financial protection to health plans
Quick-dissolve NURTEC ODT can help bring relief to patients within an hour1 
From PR Newswire
Biohaven Pharmaceuticals And Weill Cornell Medicine Collaborate To Initiate Proof Of Concept Trial With CGRP Receptor Antagonist In Plaque Psoriasis
- Weill Cornell Medicine's Dr. Richard Granstein, M.D., Chairman of Dermatology, will collaborate with Biohaven to study a Calcitonin Gene-Related Peptide (CGRP) receptor-antagonist in plaque... 
From PR Newswire
Biohaven Pharmaceuticals Inaugural Partner Of National Ataxia Foundation's Drug Development Collaborative
- National Ataxia Foundation (NAF) Drug Development Collaborative to cultivate resources that facilitate research and development of new potential treatments for Ataxia, a set of severe and... 
From PR Newswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account